CompletedNot Applicable

Prevalence of Antibodies Against SARS-CoV-2 Virus That Causes COVID-19 in Tübingen Children

Germany2,380 participantsStarted 2020-07-02

Plain-language summary

This is a prospective, longitudinal study to determine the incidence of SARS-COV-2 infection in children and adolescents by measuring specific antibodies in non-invasive saliva sampled in kindergartens and schools in a defined city area. The study includes an additional arm to validate the ELISA for anti-SARS-COV-2 reactive antibody measurements in saliva compared against blood collected in adult volunteers in a bimonthly follow-up period for 12 months.

Who can participate

Age range1 Year – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children from 1 months to 18 years * Written informed consent of the parent/legal guardian (study population is minor) * Written assent when children are ≥ 12 years * Enrolled in a kita, kindergarden, primary, or secondary school located in Tübingen Adult population: * Individuals \>18 years who recovered from a confirmed SARS-CoV-2 infection. * Or individuals \> 18 years with an unknown status of previous SARS-CoV-2 infection Exclusion Criteria: * Unwilling to give consent

What they're measuring

Incidence of SARS-CoV-2 infection in infants, children and adolescents

Timeframe: 12 months

Trial details

NCT IDNCT04581889

SponsorUniversity Hospital Tuebingen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-07-31

View on ClinicalTrials.gov More Severe Acute Respiratory Syndrome trials